Fresh Tracks Therapeutics, Inc. stock is down -0.11% since 30 days ago. The next earnings date is Mar 28, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 41.94% of the previous 30 December’s closed higher than November.
Brickell Biotech, Inc. engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofironium bromide, which has completed Phase III clinical trials for the. treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor, and BBI10, a covalent stimulator of interferon genes inhibitor.